Drugs / SER-155
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06801067 | Jan 2025 → Jan 2027 expected | diarrheal disease, enterocolitis | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04995653 | Nov 2021 → Jul 2024 | disease related to hematopoietic stem cell transplant | Seres Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SER-155 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04995653 ↗ |
| Modality | Other / unclassified | “Cultivated Multi-Strain Live Bacterial Therapeutic” NCT06801067 ↗ |
| Route | Oral | “encapsulated for oral administration” NCT06801067 ↗ |